Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
200 participants
OBSERVATIONAL
2021-09-30
2026-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
MS Detection of Somatic Mutations in Hematological Malignancies
NCT03771079
Detection of IDH2 Mutations and Monitoring Molecular Residual Disease in Patients With AML
NCT03537560
STRucturation of Transcript Analysis of Genes Involved in Hereditary Cancers
NCT06861621
Determine the Frequency of Variants in the GBA/PSAP Genes in Patients With MM or MGUS
NCT06559033
Integrated Multiomics and Multilevel Characterization of Haematological Disorders and Malignancies
NCT04298892
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with suspected hemopathies for whom we receive a sample for diagnosis in the chromosomal genetics laboratory or for whom a diagnosis of hemopathy has already been made.
* No objection made or consent given
Exclusion Criteria
* Refusal to participate
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Brest
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHRU de Brest
Brest, , France
CH Morlaix, service d'hémato clinique
Morlaix, , France
CHIC, service d'hémato clinique
Quimper, , France
CH St Brieuc, service d'hémato clinique
Saint-Brieuc, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Christophe NICOL, MD
Role: primary
Léanig LE CLEACH, MD
Role: primary
Cédric DUCLOS, MD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CARTOGEN - 29BRC21.0211
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.